2018 West/Central CME

March 15-17, 2018 in Banff, Alberta

Scientific Program

The scientific program is subject to changes.


Dr. Robert Tanguay MD

Vieux Quebec QC
Dr. Tanguay completed his B.Sc. (Hons.) in Neuroscience at the University of Lethbridge in Alberta and attended medical school at the University of Calgary where he continued on to complete his residency in Psychiatry. Dr. Tanguay completed fellowships in Addictions Medicine with the department of psychiatry, certified with the International Society for Addiction’s Medicine (ISAM), and Pain Medicine with the department of anesthesia. He is currently the Medical Lead of the Transitional Pain Program at Caleo Health and he has helped initiate the first publicly funded Opioid Taper Program for Chronic Non-Cancer Pain at the Opioid Dependency Program in Calgary. He is an authority in opioid prescribing, the effects of opioids on functioning, opioid tapering in chronic non-cancer pain (CNCP), opioid addiction, and medical marijuana. Dr. Tanguay has been invited to be a keynote, plenary, and panel speaker at national and international conferences, as well as for local events, and is a Clinical Lecturer at the University of Calgary, Cumming School of Medicine, for the Department of Psychiatry.


I have a relationship with a for-profit and/or a not-for-profit organization to disclose:

- Direct financial payments including receipt of honoraria: Indivior (Speaker), Canopy (Speaker), Pfizer (Speaker), Otsuka (Speaker)

- Membership on advisory boards or speakers’ bureaus: Lundbeck (Ad board), Indivior (Ad board), Allergen (Ad board)

- Funded grants or clinical trials: Canopy (Conference Funding), Lundbeck (Conference Funding), Otsuka (Conference Funding), Pfizer (Conference Funding), Perdue (Conference Funding), Shire (Conference Funding), Jansen (Conference Funding), Sunovioan (Conference Funding).

I do intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).